|
1
|
Obayashi S, Horiguchi J, Higuchi T,
Katayama A, Handa T, Altan B, Bai T, Bao P, Bao H, Yokobori T, et
al: Stathmin1 expression is associated with aggressive phenotypes
and cancer stem cell marker expression in breast cancer patients.
Int J Oncol. 51:781–790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Espinoza-Sánchez NA, Vadillo E, Balandrán
JC, Monroy-García A, Pelayo R and Fuentes-Pananá EM: Evidence of
lateral transmission of aggressive features between different types
of breast cancer cells. Int J Oncol. 51:1482–1496. 2017. View Article : Google Scholar :
|
|
5
|
Zhao L, Liu Y, Tong D, Qin Y, Yang J, Xue
M, Du N, Liu L, Guo B, Hou N, et al: MeCP2 promotes gastric cancer
progression through regulating FOXF1/Wnt5a/β-Catenin and MYOD1/
Caspase-3 signaling pathways. EBioMedicine. 16:87–100. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raman V, Fuentes Lorenzo JL, Stashenko EE,
Levy M, Levy MM and Camarillo IG: Lippia origanoides extract
induces cell cycle arrest and apoptosis and suppresses NF-κB
signaling in triple-negative breast cancer cells. Int J Oncol.
51:1801–1808. 2017. View Article : Google Scholar :
|
|
7
|
Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q,
Ganesan N, Etzel CJ, Gullett A, Albarracin CT and Bedrosian I:
Suppression of Akt-mTOR pathway-a novel component of oncogene
induced DNA damage response barrier in breast tumorigenesis. PLoS
One. 9:e970762014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Byler S, Goldgar S, Heerboth S, Leary M,
Housman G, Moulton K and Sarkar S: Genetic and epigenetic aspects
of breast cancer progression and therapy. Anticancer Res.
34:1071–1077. 2014.PubMed/NCBI
|
|
9
|
Zhao LY, Tong DD, Xue M, Ma HL, Liu SY,
Yang J, Liu YX, Guo B, Ni L, Liu LY, et al: MeCP2, a target of
miR-638, facilitates gastric cancer cell proliferation through
activation of the MEK1/2-ERK1/2 signaling pathway by upregulating
GIT1. Oncogenesis. 6:e3682017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hyrina A, Olmstead AD, Steven P, Krajden
M, Tam E and Jean F: Treatment-induced viral cure of hepatitis c
virus-infected patients involves a dynamic interplay among three
important molecular players in lipid homeostasis: Circulating
microRNA (miR)-24, miR-223, and proprotein convertase
subtilisin/kexin type 9. EBioMedicine. 23:68–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao LY, Yao Y, Han J, Yang J, Wang XF,
Tong DD, Song TS, Huang C and Shao Y: miR-638 suppresses cell
proliferation in gastric cancer by targeting Sp2. Dig Dis Sci.
59:1743–1753. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu J, Lin H, Li G, Sun Y, Chen J, Shi L,
Cai X and Chang C: The miR-367-3p increases sorafenib chemotherapy
efficacy to suppress hepatocellular carcinoma metastasis through
altering the androgen receptor signals. EBioMedicine. 12:55–67.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Selbach M, Schwanhäusser B, Thierfelder N,
Fang Z, Khanin R and Rajewsky N: Widespread changes in protein
synthesis induced by microRNAs. Nature. 455:58–63. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi M, Liu D, Shen B and Guo N: Helpers of
the cellular gatekeeper-miRNAs dance in P53 network. Biochim
Biophys Acta. 1805:218–225. 2010.
|
|
15
|
Sahu A, Jha PK, Prabhakar A, Singh HD,
Gupta N, Chatterjee T, Tyagi T, Sharma S, Kumari B, Singh S, et al:
MicroRNA-145 impedes thrombus formation via targeting tissue factor
in Venous thrombosis. EBioMedicine. 26:175–186. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng Y, Lv X, Wang X, Wang B, Shao X,
Huang Y, Shi L, Chen Z, Huang J and Huang P: MiR-181b promotes
chemoresistance in breast cancer by regulating Bim expression.
Oncol Rep. 35:683–690. 2016. View Article : Google Scholar
|
|
17
|
Ji Y, Han Z, Shao L and Zhao Y: Evaluation
of in vivo antitumor effects of low-frequency ultrasound-mediated
miRNA-133a microbubble delivery in breast cancer. Cancer Med.
5:2534–2543. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H, Yang T, Shang D and Sun Z: miR-1254
promotes lung cancer cell proliferation by targeting SFRP1. Biomed
Pharmacother. 92:913–918. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Q, Shen W, Li X, Zhang L and Jin X: The
lncRNA n340790 accelerates carcinogenesis of thyroid cancer by
regulating miR-1254. Am J Transl Res. 9:2181–2194. 2017.PubMed/NCBI
|
|
20
|
Lu M, Chen WH, Wang CY, Mao CQ and Wang J:
Reciprocal regulation of miR-1254 and c-Myc in oral squamous cell
carcinoma suppresses EMT-mediated metastasis and tumorinitiating
properties through MAPK signaling. Biochem Biophys Res Commun.
484:801–807. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sherwood V, Recino A, Jeffries A, Ward A
and Chalmers AD: The N-terminal RASSF family: A new group of
Ras-association-domain-containing proteins, with emerging links to
cancer formation. Biochem J. 425:303–311. 2010. View Article : Google Scholar
|
|
22
|
Zheng X, Dong Q, Zhang X, Han Q, Han X,
Han Y, Wu J, Rong X and Wang E: The coiled-coil domain of oncogene
RASSF 7 inhibits hippo signaling and promotes non-small cell lung
cancer. Oncotarget. 8:78734–78748. 2017.PubMed/NCBI
|
|
23
|
Lock FE, Underhill-Day N, Dunwell T,
Matallanas D, Cooper W, Hesson L, Recino A, Ward A, Pavlova T,
Zabarovsky E, et al: The RASSF8 candidate tumor suppressor inhibits
cell growth and regulates the Wnt and NF-κB signaling pathways.
Oncogene. 29:4307–4316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang L, Liu W, Zhang YP and Huang XR: The
miR-224 promotes non-small cell lung cancer cell proliferation by
directly targeting RASSF8. Eur Rev Med Pharmacol Sci. 21:3223–3231.
2017.PubMed/NCBI
|
|
25
|
He C, Wang L, Zhang J and Xu H:
Hypoxia-inducible microRNA-224 promotes the cell growth, migration
and invasion by directly targeting RASSF8 in gastric cancer. Mol
Cancer. 16:352017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang Y, Li Y, Wang FF, Lv W, Xie X and
Cheng X: Over-expressed miR-224 promotes the progression of
cervical cancer via targeting RASSF8. PLoS One. 11:e01623782016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hesson LB, Dunwell TL, Cooper WN,
Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD,
Maher ER and Latif F: The novel RASSF6 and RASSF10 candidate tumour
suppressor genes are frequently epigenetically inactivated in
childhood leukaemias. Mol Cancer. 8:422009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schagdarsurengin U, Richter AM, Wohler C
and Dammann RH: Frequent epigenetic inactivation of RASSF10 in
thyroid cancer. Epigenetics. 4:571–576. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu W, Wang J, Wang L, Qian C, Qian Y,
Xuan H, Zhuo W, Li X, Yu J and Si J: Ras-association domain family
10 acts as a novel tumor suppressor through modulating MMP2 in
hepatocarcinoma. Oncogenesis. 5:e2372016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Richter AM, Walesch SK and Dammann RH:
aberrant promoter methylation of the tumour suppressor RASSF10 and
its growth inhibitory function in breast cancer. Cancers (Basel).
8:262016. View Article : Google Scholar
|
|
31
|
Li X, Liang Q, Liu W, Zhang N, Xu L, Zhang
X, Zhang J, Sung JJ and Yu J: Ras association domain family member
10 suppresses gastric cancer growth by cooperating with GSTP1 to
regulate JNK/c-Jun/AP-1 pathway. Oncogene. 35:2453–2464. 2016.
View Article : Google Scholar
|
|
32
|
Lu D, Ma J, Zhan Q, Li Y, Qin J and Guo M:
Epigenetic silencing of RASSF10 promotes tumor growth in esophageal
squamous cell carcinoma. Discov Med. 17:169–178. 2014.PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) methods. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
34
|
Padi SK, Zhang Q, Rustum YM, Morrison C
and Guo B: MicroRNA-627 mediates the epigenetic mechanisms of
vitamin D to suppress proliferation of human colorectal cancer
cells and growth of xenograft tumors in mice. Gastroenterology.
145:437–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gong C, Tan W, Chen K, You N, Zhu S, Liang
G, Xie X, Li Q, Zeng Y, Ouyang N, et al: Prognostic value of a
BCSC-associated microRNA signature in hormone receptor-positive
HER2-negative breast cancer. EBioMedicine. 11:199–209. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zheng Q, Cui X, Zhang D, Yang Y, Yan X,
Liu M, Niang B, Aziz F, Liu S, Yan Q, et al: miR-200b inhibits
proliferation and metastasis of breast cancer by targeting
fucosyltransferase IV and α1, 3-fucosylated glycans. Oncogenesis.
6:e3582017. View Article : Google Scholar
|
|
37
|
Lee CM, Yang P, Chen LC, Chen CC, Wu SC,
Cheng HY and Chang YS: A novel role of RASSF9 in maintaining
epidermal homeostasis. PLoS One. 6:e178672011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ejaz A, Mitterberger MC, Lu Z, Mattesich
M, Zwierzina ME, Hörl S, Kaiser A, Viertler HP, Rostek U, Meryk A,
et al: Weight loss upregulates the small gtpase diras3 in human
white adipose progenitor cells, which negatively regulates
adipogenesis and activates autophagy via akt-mtor inhibition.
EBioMedicine. 6:149–161. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu N, Lao Y, Zhang Y and Gillespie DA:
AKT: A double-edged sword in cell proliferation and genome
stability. J Oncol. 2012:9517242012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang J, Tong DD, Xue M, Jiang QY, Wang
XF, Yang PB, Ni L, Zhao LY and Huang C: FAM196B acts as oncogene
and promotes proliferation of gastric cancer cells through AKT
signaling pathway. Cell Mol Biol. 63:18–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Maddika S, Ande SR, Wiechec E, Hansen LL,
Wesselborg S and Los M: Akt-mediated phosphorylation of CDK2
regulates its dual role in cell cycle progression and apoptosis. J
Cell Sci. 121:979–988. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao LY, Zhang J, Guo B, Yang J, Han J,
Zhao XG, Wang XF, Liu LY, Li ZF, Song TS, et al: MECP2 promotes
cell proliferation by activation ERK1/2 and inhibiting p38 activity
in human hepatocellular carcinoma HEPG2 cells. Cell Mol Biol.
59:OL1876–OL1881. 2013.
|
|
43
|
Juengel E, Euler S, Maxeiner S, Rutz J,
Justin S, Roos F, Khoder W, Nelson K, Bechstein WO and Blaheta RA:
Sulforaphane as an adjunctive to everolimus counteracts everolimus
resistance in renal cancer cell lines. Phytomedicine. 27:1–7. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chu X, Zhang T, Wang J, Li M, Zhang X, Tu
J, Sun S, Chen X and Lu F: Alternative splicing variants of human
Fbx4 disturb cyclin D1 proteolysis in human cancer. Biochem Biophys
Res Commun. 447:158–164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li T, Kon N, Jiang L, Tan M, Ludwig T,
Zhao Y, Baer R and Gu W: Tumor suppression in the absence of
p53-mediated cell cycle arrest, apoptosis, and senescence. Cell.
149:1269–1283. 2012. View Article : Google Scholar : PubMed/NCBI
|
